celecoxib has been researched along with Barrett Esophagus in 11 studies
Barrett Esophagus: A condition with damage to the lining of the lower ESOPHAGUS resulting from chronic acid reflux (ESOPHAGITIS, REFLUX). Through the process of metaplasia, the squamous cells are replaced by a columnar epithelium with cells resembling those of the INTESTINE or the salmon-pink mucosa of the STOMACH. Barrett's columnar epithelium is a marker for severe reflux and precursor to ADENOCARCINOMA of the esophagus.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To study the feasibility of chemoprevention of esophageal adenocarcinoma by celecoxib, a selective cyclooxygenase-2(COX-2) inhibitor using a rat model." | 7.78 | [An experimental study on chemoprevention of esophageal adenocarcinoma by celecoxib, a selective cyclooxygenase-2 inhibitor]. ( Lang, HJ; Liang, XH; Su, LW; Wang, YJ; Zhang, F; Zhang, T; Zhou, YA; Zhu, YF, 2012) |
| "To study the feasibility of chemoprevention of esophageal adenocarcinoma by celecoxib, a selective cyclooxygenase-2(COX-2) inhibitor using a rat model." | 3.78 | [An experimental study on chemoprevention of esophageal adenocarcinoma by celecoxib, a selective cyclooxygenase-2 inhibitor]. ( Lang, HJ; Liang, XH; Su, LW; Wang, YJ; Zhang, F; Zhang, T; Zhou, YA; Zhu, YF, 2012) |
| "Although evidence suggests that aspirin and celecoxib may reduce the risk of esophageal adenocarcinoma (EAC) in patients with Barrett's esophagus (BE), these drugs can also cause harmful side effects." | 3.74 | Patient preferences for the chemoprevention of esophageal adenocarcinoma in Barrett's esophagus. ( Broughton, DE; Gazelle, GS; Hur, C; Nishioka, NS; Ozanne, E; Yachimski, P, 2008) |
| "A series of 90 rats underwent a duodenoesophageal reflux surgery were divided into 2 groups: the control group was given a commercial chow and the celecoxib group experimental chow containing celecoxib." | 3.73 | [A COX-2 inhibitor suppresses esophageal inflammation-metaplasia-adenocarcinoma sequence in rats]. ( Fujimura, T; Miwa, K; Oyama, K, 2005) |
| "The Chemoprevention for Barrett's Esophagus Trial (CBET) was a phase IIb, multicenter, randomized, placebo-controlled trial of celecoxib in patients with Barrett's esophagus." | 2.73 | Quantitative endoscopy in the chemoprevention of Barrett's Esophagus Trial. ( Forastiere, AA; Gaudard, MA; Heath, EI; Shar, AO; Sontag, SJ; Yang, VW, 2008) |
| " Because aspirin and other nonsteroidal anti-inflammatory drugs, such as celecoxib, may decrease the risk of developing esophageal cancer, we investigated the effect of long-term administration of celecoxib in patients with Barrett's esophagus with dysplasia." | 2.73 | Secondary chemoprevention of Barrett's esophagus with celecoxib: results of a randomized trial. ( Canto, MI; Dannenberg, AJ; Forastiere, AA; Hawk, E; Heath, EI; Herman, JG; Montgomery, E; Piantadosi, S; Shar, AO; Weinstein, WM; Yang, VW, 2007) |
| "Celecoxib treatment decreased the incidence of EA in rats undergoing EJA with H." | 1.37 | Effect of Helicobacter pylori infection on Barrett's esophagus and esophageal adenocarcinoma formation in a rat model of chronic gastroesophageal reflux. ( Gao, PP; Li, J; Liu, FX; Wang, J; Wang, WH, 2011) |
| "examined Barrett's esophagus patient preferences for cancer chemoprevention with either aspirin or celecoxib." | 1.35 | Chemoprevention and Barrett's esophagus: decisions, decisions. ( Falk, GW; Jankowski, J, 2008) |
| "The Chemoprevention for Barrett's Esophagus Trial (CBET) was a phase IIb, multicenter, randomized, placebo-controlled trial of celecoxib in patients with Barrett's esophagus." | 1.35 | Modeling using baseline characteristics in a small multicenter clinical trial for Barrett's esophagus. ( Forastiere, AA; Gaudard, MA; Heath, EI; Shar, AO; Sontag, SJ; Yang, VW, 2009) |
| "The degree of inflammation, Barrett's esophagus, adenocarcinoma, COX-2 expression and PGE(2) of animals were assessed." | 1.35 | [Chemoprevention of Barrett's esophagus by celecoxib in rats]. ( Chen, X; Li, GD; Ou-Yang, Q; Wang, RH; Xiang, JY, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (72.73) | 29.6817 |
| 2010's | 3 (27.27) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Shar, AO | 3 |
| Gaudard, MA | 2 |
| Heath, EI | 3 |
| Forastiere, AA | 3 |
| Yang, VW | 3 |
| Sontag, SJ | 2 |
| Falk, GW | 1 |
| Jankowski, J | 1 |
| Hur, C | 1 |
| Broughton, DE | 1 |
| Ozanne, E | 1 |
| Yachimski, P | 1 |
| Nishioka, NS | 1 |
| Gazelle, GS | 1 |
| Wang, RH | 1 |
| Ou-Yang, Q | 1 |
| Chen, X | 1 |
| Li, GD | 1 |
| Xiang, JY | 1 |
| Triadafilopoulos, G | 1 |
| Lombard, CM | 1 |
| Jobe, BA | 1 |
| Liu, FX | 1 |
| Wang, WH | 1 |
| Wang, J | 1 |
| Li, J | 1 |
| Gao, PP | 1 |
| Zhang, T | 1 |
| Su, LW | 1 |
| Zhu, YF | 1 |
| Lang, HJ | 1 |
| Zhang, F | 1 |
| Zhou, YA | 1 |
| Liang, XH | 1 |
| Wang, YJ | 1 |
| Miwa, K | 1 |
| Oyama, K | 1 |
| Fujimura, T | 1 |
| Canto, MI | 1 |
| Piantadosi, S | 1 |
| Montgomery, E | 1 |
| Weinstein, WM | 1 |
| Herman, JG | 1 |
| Dannenberg, AJ | 1 |
| Hawk, E | 1 |
| Jacobson, GA | 1 |
| Narkowicz, C | 1 |
| Lord, R | 1 |
| Howard, BJ | 1 |
| Chung, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Chemoprevention for Barrett's Esophagus Trial (CBET)[NCT00005878] | Phase 2 | 0 participants | Interventional | 2000-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for celecoxib and Barrett Esophagus
| Article | Year |
|---|---|
Quantitative endoscopy in the chemoprevention of Barrett's Esophagus Trial.
Topics: Barrett Esophagus; Celecoxib; Cohort Studies; Cyclooxygenase Inhibitors; Endoscopy; Humans; Pyrazole | 2008 |
Secondary chemoprevention of Barrett's esophagus with celecoxib: results of a randomized trial.
Topics: Aged; Aged, 80 and over; Barrett Esophagus; Cadherins; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2 | 2007 |
9 other studies available for celecoxib and Barrett Esophagus
| Article | Year |
|---|---|
Chemoprevention and Barrett's esophagus: decisions, decisions.
Topics: Adenocarcinoma; Aspirin; Barrett Esophagus; Cardiovascular Diseases; Celecoxib; Chemoprevention; Cyc | 2008 |
Patient preferences for the chemoprevention of esophageal adenocarcinoma in Barrett's esophagus.
Topics: Adenocarcinoma; Aspirin; Barrett Esophagus; Cardiovascular Diseases; Celecoxib; Chemoprevention; Cyc | 2008 |
Modeling using baseline characteristics in a small multicenter clinical trial for Barrett's esophagus.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Barrett Esophagus; Celecoxib; Data Interpretation, Statisti | 2009 |
[Chemoprevention of Barrett's esophagus by celecoxib in rats].
Topics: Animals; Barrett Esophagus; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dinoprostone; | 2009 |
"War and Peace" with Barrett's esophagus.
Topics: Adenocarcinoma; Aged; Anti-Ulcer Agents; Antihypertensive Agents; Aspirin; Barrett Esophagus; Celeco | 2011 |
Effect of Helicobacter pylori infection on Barrett's esophagus and esophageal adenocarcinoma formation in a rat model of chronic gastroesophageal reflux.
Topics: Adenocarcinoma; Anastomosis, Surgical; Animals; Barrett Esophagus; CDX2 Transcription Factor; Celeco | 2011 |
[An experimental study on chemoprevention of esophageal adenocarcinoma by celecoxib, a selective cyclooxygenase-2 inhibitor].
Topics: Adenocarcinoma; Animals; Barrett Esophagus; Celecoxib; Cyclooxygenase 2 Inhibitors; Disease Models, | 2012 |
[A COX-2 inhibitor suppresses esophageal inflammation-metaplasia-adenocarcinoma sequence in rats].
Topics: Adenocarcinoma; Animals; Apoptosis; Barrett Esophagus; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 | 2005 |
Effect of celecoxib on cyclooxygenase-2 expression and possible variants in a patient with Barrett's esophagus.
Topics: Adult; Barrett Esophagus; Celecoxib; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Female; Humans; Py | 2007 |